(UroToday.com) In a talk presented in the Oral Presentations session of the 12th European Multidisciplinary Congress on Urological Cancers (EMUC), Dr. Aristotelis Bamias presented a subgroup analysis from the IMvigor130 trial examining the role of atezolizumab plus platinum-based chemotherapy in patients with locally advanced or metastatic urothelial carcinoma, with stratification according to the primary tumor site.